Apatinib as Second-line Treatment of Advanced Pancreatic Cancer
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The main research purpose Evaluation of objective response Apatinib second-line treatment of
advanced pancreatic cancer (ORR) and the rate of progression free survival (PFS).
Objective to study the objective and exploratory secondary research To observe the Apatinib
in second line treatment of advanced pancreatic cancer disease control rate (DCR), patients
with overall survival (OS) benefit, treatment effects on quality of life (QOL) score and drug
safety evaluation, To investigate the relationship of apatinib as second-line treatment of
advanced pancreatic cancer and the expression of vascular endothelial growth factor
receptor(VEGFR) in the serum
Phase:
Phase 2
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University